Alpha 2.0
Login Register
» Journals » Cancer Immunol Immunother

Cancer Immunology, Immunotherapy : Cii

Cancer immunology, immunotherapy: CII is a renowned scientific journal that focuses on the rapidly evolving field of cancer immunology and immunotherapy. It publishes cutting-edge research articles, reviews, and commentaries, providing a platform for scientists and clinicians to share their findings and advancements in understanding the immune system's role in cancer development and treatment. The journal aims to foster collaboration and innovation in the field, ultimately contributing to the development of novel immunotherapeutic approaches for cancer patients.
Details
Abbr. Cancer Immunol Immunother
Start 1982
End Continuing
Frequency Twelve no. a year
p-ISSN 0340-7004
e-ISSN 1432-0851
Country Germany
Language English
Specialties Oncology
Pharmacology
Allergy & Immunology
Metrics
h-index / Ranks: 1746 136
SJR / Ranks: 1630 1663
CiteScore / Ranks: 1093 11.30
JIF / Ranks: 1190 5.8
Recent Articles
1.
Lymphocyte/monocyte to lactate dehydrogenase ratio prior to lymphodepletion impact the outcomes of patients with diffused large B cell lymphoma undergoing CAR-T cell therapy
Li N, An N, Ma S, Cao J, Zhu F, Qi K, et al.
Cancer Immunol Immunother . 2025 Mar; 74(5):148. PMID: 40088299
Factors associated with outcomes of chimeric antigen receptor (CAR)-T cell therapy in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have not been fully elucidated. We explored...
2.
The prognosis prediction value of CD69+ CD8+ tissue-resident memory T cell as a novel indicator of pathologic complete response heterogeneity following different neoadjuvant therapy regimen in esophageal squamous cell carcinoma
Liu A, Liu D, Liu X, Chi Y, Guo L, Li D, et al.
Cancer Immunol Immunother . 2025 Mar; 74(5):147. PMID: 40088295
Background: Improving pathological complete response (pCR) rate is currently the main goal of neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (LA-ESCC). However, improved pCR rates do not consistently...
3.
Infectious complications distribution following CLL1 CAR-T cell therapy for acute myeloid leukemiass
Xu J, Zhang H, Zhao Y, Zhang X, Guo S, Shi X, et al.
Cancer Immunol Immunother . 2025 Mar; 74(5):149. PMID: 40088283
The CLL1-targeted chimeric antigen receptor T (CAR-T) cell therapy offers a novel therapeutic approach for refractory or relapsed acute myeloid leukemia (AML).The targeted elimination of tumor cells by CLL1 CAR-T...
4.
Navigating TAM receptor dynamics in tumour immunotherapy
Yang J, Chen G, Wang R, Song C, Yi H
Cancer Immunol Immunother . 2025 Mar; 74(5):146. PMID: 40088262
The TAM receptor family is getting more and more attention in the field of tumour immunity. Activation of TAM receptors not only aids in the survival and multiplication of tumour...
5.
Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model
Nguyen C, Vu T, Nguyen M, Tran-Nguyen T, Huynh C, Ha Q, et al.
Cancer Immunol Immunother . 2025 Mar; 74(4):145. PMID: 40072566
Neoantigen vaccines hold great promise in cancer immunotherapy, but the comparative efficacy of different vaccine platforms, particularly in the context of tumor burden (TB), remains insufficiently studied. In this research,...
6.
Preclinical investigation of anti-tumor efficacy of allogeneic natural killer cells combined with cetuximab for head and neck squamous cell carcinoma
Kim C, Han M, Kim G, Son W, Kim J, Gil M, et al.
Cancer Immunol Immunother . 2025 Mar; 74(4):144. PMID: 40063100
Head and neck squamous cell carcinoma (HNSCC) presents a significant therapeutic challenge because of the limited effectiveness of current treatments including immunotherapy and chemotherapy. This study investigated the potential of...
7.
Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies
Lu Z, Sun G, Li J, Zhao J, Wang Z, Qian D, et al.
Cancer Immunol Immunother . 2025 Mar; 74(4):138. PMID: 40056201
Background And Aims: This individual patient data pooled analysis aimed to evaluate the effectiveness, safety, and patterns of use of camrelizumab in a large cohort of advanced esophageal cancer (AEC)...
8.
Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab
Wang X, Li T, Slebos R, Chaudhary R, Guevara-Patino J, Bonomi M, et al.
Cancer Immunol Immunother . 2025 Mar; 74(4):142. PMID: 40056190
Immunotherapy holds significant promise for treating head and neck squamous cell carcinoma (HNSCC), yet responses are limited to a subset of patients. This research investigates whether analyzing the peripheral T-cell...
9.
Microbial dysbiosis with tryptophan metabolites alteration in lower respiratory tract is associated with clinical responses to anti-PD-1 immunotherapy in advanced non-small cell lung cancer
Chen X, Ju Q, Qiu D, Zhou Y, Wang Y, Zhang X, et al.
Cancer Immunol Immunother . 2025 Mar; 74(4):140. PMID: 40056186
Lower respiratory tract microbiome constitutes a unique immune microenvironment for advanced non-small cell lung cancer as one of dominant localized microbial components. However, there exists little knowledge on the associations...
10.
ZEB1 transcription factor induces tumor cell PD-L1 expression in melanoma
Wirbel C, Durand S, Boivin F, Plaschka M, Benboubker V, Grimont M, et al.
Cancer Immunol Immunother . 2025 Mar; 74(4):141. PMID: 40056177
Tumor cells can evade antitumor immune response by expressing the PD-L1 ligand, leading to the inhibition of PD-1-expressing T lymphocytes. The mechanisms that regulate PD-L1 expression in cancer cells are...